The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous T-DXd treatment.
Metastatic HER2-positive Breast Cancer
The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous T-DXd treatment.
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
-
Arizona Oncology Tucson - Wilmot, Tucson, Arizona, United States, 85711
Rocky Mountain Cancer Centers, Denver, Colorado, United States, 80218
Minnesota Oncology Hematology, Coon Rapids, Minnesota, United States, 55433
Messino Cancer Center, Asheville, North Carolina, United States, 28806
Oncology Hematology Care (OHC), Cincinnati, Ohio, United States, 45226
Sarah Cannon Research Institute, Nashville, Tennessee, United States, 37203
Texas Oncology - Fort Worth, Fort Worth, Texas, United States, 76104
Virginia Cancer Specialists, Fairfax, Virginia, United States, 22031
Virginia Oncology Associates, Sentara Health, Norfolk, Virginia, United States, 23502
Blue Ridge Cancer Care, Roanoke, Virginia, United States, 24014
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Jazz Pharmaceuticals,
2031-11-26